Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2008 in Acromegaly
NCT07623824Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2026
- Primary completion
- Jul 2029
01
Overview
Phase 3, randomised, open-label trial of SYHX2008 in acromegaly (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Proportion of patients with an IGF-1 index <= 1.0 at 28 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
SYHX2008
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT07623824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623824.